Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial

Vascular Health and Risk Management

Volumn 6, Issue 1, 2010, Pages 261-271

  Grimm, Richard ^a   Malik, Mobin ^a   Yunis, Carla ^b   Sutradhar, Santosh ^b   Kursun, Attila ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b PFIZER INC   (United States)

Author keywords

Blood pressure; Calcium channel blocker; Low density lipoprotein cholesterol; Statin

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; AMLODIPINE, ATORVASTATIN DRUG COMBINATION; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; PYRROLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTHROPATHY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; LIFESTYLE MODIFICATION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; SPRAIN; TINNITUS; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; DYSLIPIDEMIA; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RISK; RISK ASSESSMENT; RISK FACTOR; TABLET; TIME; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DYSLIPIDEMIAS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; LIPIDS; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; PYRROLES; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; TABLETS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 77955896091     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/vhrm.s7710     Document Type: Article

References (14)

1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart Disease and Stroke Statistics 2009 Update. A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation. 2009;119:e1-e161.
2. Kannel WB. Fifty years of Framingham Study contributions to understanding hypertension. J Hum Hypertens. 2000;14:83-90.
3. Ansell BJ. Evidence for a combined approach to the management of hypertension and dyslipidemia. Am J Hypertens. 2005;18: 1249-1257.
4. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
5. NCEP ATP III. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
6. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165:1147-1152.
7. Cherry SB, Benner JS, Hussein MA, et al. The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients. Value Health. 2009;12:489-497.
8. American Heart Association. Dietary approaches to prevent and treat hypertension: a scientifc statement by the American Heart Association. Hypertension. 2006;47:296-308.
9. Grundy SM I CJ, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44: 720-732.
10. NCEP. National Cholesterol Education Program of the National Institutes of Health National Heart, Lung, and Blood Institute. Spreadsheet-based 10-year risk assessment tool; 2008.
11. Neutel JM, Bestermann WH, Dyess EM, et al. The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multi-center study. J Clin Hypertens. 2009;11:22-30.
12. Golomb BA, Dimsdale JE, White HL, et al. Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial. Arch Intern Med. 2008;168:721-727.
13. Feldstein CA. Statins as antihypertensives. Recent Patents Cardiovasc Drug Discov. 2008;3:92-97.
14. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158.